Trial Profile
AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Lysosomal storage diseases
- Focus Expanded access; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease; Synageva BioPharma
- 05 Mar 2015 New trial record